Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism. Read More »

Rezolut is a national emerging platform of diagnostic medical imaging services. With a focus on four key platforms, our vision is to provide top-notch patient care partnered with innovative technology — to achieve better health outcomes.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Our antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital ...

Nov 7, 2024 · Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Feb 4, 2025 · RZLT | Complete Rezolute Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Rezolute is committed to providing safe and effective therapies for patients and supports the need for EAPs. Through our EAP, we aim to provide RZ358 to patients who have experienced its therapeutic benefit in our clinical studies and wish to continue their treatment post-trial.

Rezolute received FDA clearance for an investigational new drug (IND) application for a Phase 3 registrational study of ersodetug for the treatment of hypoglycemia due to tumor HI.

2 days ago · Rezolute, Inc. Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation.

Nov 7, 2024 · Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI ...